It is noteworthy that in the exploratory post-hoc analyses of the CLL14 trial, which investigated venetoclax-obinutuzumab in elderly patients with CLL, achieving undetectable measurable residual disease (i.e., uMRD6) status was associated with higher pro-apoptotic BCL2L11 expression [61]. Here, BCL2L11 is linked to B-cell chronic lymphocytic leukemia.